Dr. Brian Feldman

MD, MSc, FRCPC

Biography

Dr. Brian Feldman is Professor of Pediatrics, the Institute of Medicine, and the Institute of Health Policy Management & Evaluation at the University of Toronto. He is Division Head of Rheumatology at The Hospital for Sick Children. Dr. Feldman graduated from the University of Western Ontario (MD, 1985) and he did further graduate training in clinical epidemiology at the University of Toronto (MSc, 1994). He interned at the Mount Sinai Hospital in Toronto and went on to do a core pediatric residency at the Children’s Hospital of Eastern Ontario. Dr. Feldman returned to Toronto to be an associate chief resident at The Hospital for Sick Children. He stayed on there to complete a fellowship in pediatric rheumatology.

Dr. Feldman’s main focus has been in clinical research in the field of childhood rheumatic disease. Recognizing the challenges involved in the study of rare disease Dr. Feldman has worked to improve the tools available to assist in this research. He has worked at developing and refining outcome measurement tools for use in clinical trials and in outcome studies. He has developed innovative methodologies for the study of new therapies (e.g. the Randomized Placebo Phase Design) and refined and tested powerful existing methods (e.g. Bayesian meta-analysis of n-of-1 randomized trials). Dr. Feldman has made contributions to the understanding of the prognosis and treatment of juvenile dermatomyositis, the cost-effective prevention of arthropathy in severe hemophilia, the course and outcome of systemic-onset juvenile idiopathic arthritis and juvenile SLE, and the role of fitness and exercise in childhood chronic diseases including arthritis and fibromyalgia.

Dr. Feldman’s research, by its nature, is collaborative. As such he is a member of the Pediatric Rheumatology Collaborative Study Group, the Canadian Alliance of Pediatric Rheumatology Investigators, the International Myositis Assessment Criteria study group, and other collaborative organizations. He was one of the founding members of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was the head of the protocol evaluation subcommittee and chair of the Juvenile Dermatomyositis subcommittee. Dr. Feldman is also a former member of the Steering Committee, member Physical Therapy Expert Working Group, and former Outcome Measures Expert Working Group of the International Prophylaxis Study Group.

Key Publications

World Federation of Hemophilia 2012 World Congress, Paris, France, July 10, 2012, Plenary Session. Implementing musculoskeletal outcome assessments in clinical practice.
World Federation of Hemophilia 2012 World Congress, Paris. France. July 10. 2012. Session Chair: Outcome assessment and limitations.
World Federation of Hemophilia 2012 World Congress, Paris, France, July 10, 2012. Quality of life assessment.
World Federation of Hemophilia 2013 World Congress, Seefeld. Austria, March 15, 2013. Musculoskeletal Outcome Assessment.
CHPS and other snacks: Which one to choose when shopping the ‘aisle’ of prophylaxis? Winnipeg MB. May 25, 2013. CHPS: A 15-year Journey: Key Findings & Lessons Learned.

Key Institutions

The Hospital for Sick Children
Department of Paediatrics, Division of Rheumatology, and The Research Institute
Toronto, Canada
The University of Toronto
Departments of Pediatrics and Institute of Health Policy Management & Evaluation in the Dalla Lana School of Public Health
Toronto, Canada

Current Positions/Chairs

Division Head
Department of Rheumatology at The Hospital for Sick Children
Professor of Pediatrics
The Institute of Medicine, Institute of Health Policy Management & Evaluation at the University of Toronto
Senior Scientist
Child Health Evaluative Sciences, The Hospital for Sick Children
Founding Member
Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was the head of the protocol evaluation subcommittee and chair of the Juvenile Dermatomyositis subcommittee
Chair
Ho Family Chair in Autoimmune Research

Research Interests

Clinical research in the field of childhood rheumatic disease
Developing and refining outcome measurement tools for use in clinical trials and outcome studies in rare disease groups

Research Activities

Canadian Hemophilia Dose Escalation Primary Prophylaxis (CHPS-3) Observational Extension Study. Feldman UM, Ulanchette V, Rivard GE, lsraels 5, Chan A, Lillicrap D, Willan A. Einarson T. Babyn P, Doria A, Wintle R: Bayer Inc. (583,671.71 2010-2012) P1
The Hemophilia Joint Health Score v2.1 Validation in Adult Patients Study: (HJHS – VAPS) A multi-centre international study. St-Louis J, Feldman BM: International Prophylaxis Study Group ( 88,735.19 12/2014 – 06/2016 )
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World: The Sao Paulo-Toronto Hemophilia Study. Feldman BM, Blanchette V: Baxter Healthcare Corporation (219,637.94 02/2010-02/2013) P1
Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults with Severe Hemophila. Feldman BM, Rivard G, Carcao M, St-Louis J, Teitel J, Pulleneyegum E, Blanchette V: Bayer Partnership Fund ($250,000 11/2007 – 0W2010) P1
Models of Care Catalyst Grant. Feldman BM, Levy D. Arthritis Society ($54.780 10/2013 – 09/2014, extended to 09/2015)
Effects of Creatine Supplementation on Muscle Pathophysiology in Children with Dermatomyositis, Stephens S. Feldman BM. Wells GD. Tien I. Schuize A. Rare Disease Foundation and the BC Childrerisliospital Foundation (BCCNF) (3,500 2012-2013)P1
The Effect of creatine supplementation on muscle function in childhood myositis, Feldman BM, Stephens S, Wells GD, Tien I, Schulze A, Schneiderman J. The Myositis Association (100,000 2014-2016) PI
Cost-effectiveness of escalating dose factor VIII prophylaxis in severe haemophilia A. Blanchette V (Principal Investigator), Feldman B: Bayer Canada/Canadian Red Cross Society Blood Services Research and Development Programme ($473,000 1996 – 2001)
An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A. Blanchette V (Principal Investigator), Feldman B: Bayer Canada ($585,076.52 2003-2006)
An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A Extension. Blanchette V (Principal Investigator), Feldman B (Co-Principal Investigator): Bayer Canada ($
An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A (Canadian haemophilia primary prophylaxis observational extension study). Blanchette V (Principal Invest
An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A (Canadian haemophilia primary prophylaxis observational extension study and pharmacokinetic substudy).

Publications

March 25, 2022

The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study.

Authors

St-Louis J, Abad A, Funk S, Tilak M, Classey S, Zourikian N, McLaughlin P, Lobet S, Hernandez G, Akins S, Wells AJ, Manco-Johnson M, John J, Austin S, Chowdary P, Hermans C, Nugent D, Bakeer N, Mangles S, Hilliard P, Blanchette VS, Feldman BM.

Citation

Res Pract Thromb Haemost. 2022 Mar 25;6(2):e12690. doi: 10.1002/rth2.12690. Erratum in: Res Pract Thromb Haemost. 2022 Apr 25;6(3):e12713. PMID: 35356667; PMCID: PMC8956786.

April 1, 2021

Musculoskeletal Ultrasound in Hemophilia: results and recommendations from a global survey and consensus meeting

Authors

Bakeer N, Dover S, Babyn P, Feldman BM, Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Sridhar Gibikote S,Goddard N , Hilliard P, Keshava S, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O’Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Logi Vidarsson L, Blanchette, VS

Citation

Res Pract Thromb Haemost . 2021 Jul 10;5(5):e12531. doi: 10.1002/rth2.12531. eCollection 2021 Jul.

October 15, 2020

Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS.

Authors

Kuijlaars IAR, van der Net J, Feldman BM, Aspdahl M, Bladen M, de Boer W, CuestaBarriuso R, Matlary RED, Funk SM, Hilliard P, John JA, Kempton CL, de Kleijn P, MancoJohnson M, Petrini P, Poonnoose P, St-Louis J, Thomas S, Timmer MA, Trakymiene SS, van Vlimmeren L, Fischer K

Citation

Haemophilia. 2020 Oct 15. doi: 10.1111/hae.14180. Epub ahead of print. PMID:33058441.

August 11, 2020

Reference Ranges of HJHS Scores in Healthy Adult Males without Hemophilia

Authors

St-Louis J , Abad A , Akin S , Austin S , Chowdary P , Classey S , Funk S , Hernandez G ,Hilliard P, Manco-Johnson M , S. Mangles S , McLaughlin P , Nugent D , Shapiro A, Srivastava A , Tilak M , Wells A , Zourikian N , Blanchette V , Feldman BM.

Citation

Research Practice in Thrombosis and Haemostasis 2020; 4 (S1): 521, PB1032.

May 10, 2018

Elevated HJHS Scores in healthy adult males without hemophilia

Authors

Feldman B, Zourikian N, Funk S, Tilak M, Lobet S, Manco-Johnson M, Srivastava A, Hilliard P, Tiseo L and St-Louis J

Citation

Haemophilia 2018; 24 (S5): 176, W- FPMED01- 002

March 1, 2016

Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Authors

Berger K, Feldman BM, Wasserman J, Schramm W, Blanchette VS, Fischer K on behalf of the Outcome Measures Expert Working Group of the IPSG

Citation

Haematologica; March 2016 101: 266-268

April 17, 2012

Hemophilia Prophylaxis: How can we justify the costs?

Authors

Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, and Schramm W.

Citation

Haemophilia 2012 Sept; 18 (5): 680-684.

January 28, 2011

Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the Hemophilia Joint Health Score (HJHS).

Authors

Feldman BM, Funk S, Bergstrom B-M, Zourikian N, Hilliard P, van der Net J, Engelbert RHH, Petrini P, van den Berg M , Manco-Johnson M, Rivard GE, Abad A, and Blanchette VS.

Citation

Arthritis Care & Research 2011 Feb; 63 (2):223-30.

July 1, 2008

The Haemophilia Joint Health Score (HJHS) international validation study.

Authors

Feldman B M, Funk S, Hilliard P, van der Net J, Zourikian N, Bergstrom B-M, Engelbert RHH, Abad A, Petrini P, Manco-Johnson M, and on behalf of the International Prophylaxis Study Group.

Citation

Haemophilia 2008, 14 (S2), 83 # 12 PO 85.

July 1, 2008

A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG).

Authors

Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.

Citation

Haemophilia 2008, 14 (S2), 133 # 24 PO 17.

June 1, 2008

A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG)

Authors

Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.

May 16, 2008

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG).

Authors

Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, and Blanchette V.

Citation

Haemophilia 2008, 14 (Suppl. 3), 162-169.

November 13, 2007

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of the International Prophylaxis Study Group.

Authors

Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Mantovani L, Hoots K,, Schramm W, van Hout BA, Willan AR, and Feldman BM.

Citation

Haemophilia 2008 Jan; 14 (1):127 -132.

September 10, 2007

The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) Symposium.

Authors

Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W and Blanchette VS.

Citation

Haemophilia 2007 Nov; 13 (6): 745-749.

August 15, 2006

Hemophilia joint health score reliability study.

Authors

Hilliard P, Funk S, Zourikian N, Bergstrom B-M, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, and Feldman BM.

Citation

Haemophilia 2006 Sept; 12: 518 – 525.

August 15, 2006

Reliability study of the Hemophilia Joint Health Score.

Authors

Hilliard P, Funk S, Zourikian N, Bergstrom B-M, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, and Feldman BM.

Citation

Haemophilia 2004 Oct; 10 (S3): 79 # 16 S 03.

January 21, 2005

Proceedings of the International Haemophilia Prophylaxis Study Group Meeting November 2003, Montreal, PQ, Canada.

Authors

Feldman BM, Babyn P, Doria AS, Heijnen L, Jacobson J, Kilcoyne R, Lundin B, Manco-Johnson M, McLimont M, Petrini P, Pettersson H, and Blanchette VS on behalf of the IPSG.

Citation

Haemophilia 2005 Jan; 11: 58 – 63.

October 17, 2004

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions

Authors

Doria AS, Feldman BM, Lundin B, and Blanchette VS on behalf of the IPSG

Citation

Haemophilia . 2004 Oct:10 Suppl 4:88-93. doi: 10.1111

October 8, 2004

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions.

Authors

Manco-Johnson MJ, Pettersson H, Petrini P, Babyn PS, Bergstrom B-M, Bradley CS , Doria AS, Feldman BM, Funk S, Hilliard P, Kilcoyne R, Lundin B, Nuss R, Rivard G, Schoenmakers MA, van den berg M, Wiedel J, Zourikian N, and Blanchette VS.

Citation

Haemophilia 2004 Oct; 10 (S4):88 – 93.